Athira Pharma, Inc. (NASDAQ: ATHA), a prominent biopharmaceutical company specializing in neurodegenerative diseases, has announced the completion of patient dosing in the Phase 2/3 LIFT-AD clinical trial. This trial is pivotal in evaluating fosgonimeton, a novel treatment for individuals with mild-to-moderate Alzheimer’s disease (AD). Athira is set to unveil topline results by the end of […]
The U.S. Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt), an Alzheimer’s treatment developed by Eli Lilly and Company (NYSE: LLY). This treatment, specifically designed for adults with early symptomatic Alzheimer’s disease, includes those with mild cognitive impairment (MCI) and the mild dementia stage of Alzheimer’s, with confirmed amyloid pathology. Priced at $350 million […]
BioArctic AB’s partner Eisai has initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (Leqembi) subcutaneous autoinjector for weekly maintenance dosing. This follows the Fast Track designation granted by the FDA. In the U.S., Leqembi is indicated for the treatment of Alzheimer’s disease in […]
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) has entered into a new research evaluation agreement with Eisai Co., Ltd. The collaboration focuses on BAN2802, a potential Alzheimer’s disease treatment that integrates BioArctic’s proprietary BrainTransporter technology with an undisclosed Alzheimer drug candidate. At the conclusion of this evaluation phase, Eisai will review the data and determine […]
Global Health Update — Promising developments in the fight against Alzheimer’s disease could significantly alter the landscape of treatment and prevention within the next decade. Experts are optimistic about the introduction of an effective drug to treat Alzheimer’s soon, with a potential vaccine to prevent the disease possibly available within ten years. Advances in Alzheimer’s […]